While the Supreme Court just granted certiorari in Myriad, case law surrounding the patent-eligibility of diagnostic and therapeutic personalized medicine has continued to develop in the wake of Mayo v. Prometheus. The good news for innovators is that the USPTO is still granting patents in the field of personalized medicine. The bad news is that the Federal Circuit is still invalidating claims as “indistinguishable” from those presented by Prometheus.
Tag Archives: Intema
Twitter Updates
@PharmaPatents PharmaPatents' Recent Twitter Posts
- RT @LXBN: USPTO Launches New After Final Consideration Pilot Program To Reduce Requests f/ Continued Examination http://t.co/0wZkObsUp6 @Ph…
(about 1 day ago) - New article: USPTO Launches New After Final Consideration Pilot Program To Reduce Requests For http://t.co/ftDOBYcEgK ##patent
(about 1 day ago) - RT @LXBN: Supreme Court Finds For Monsanto In Seed Harvesting Case http://t.co/otl9Pbs0Q2 - @PharmaPatents
(about 5 days ago) - RT @priorsmart: Just read: Supreme Court Finds For Monsanto In Seed Harvesting Case - http://t.co/70U6m8vVvw [at @pharmapatents] #patent
(about 5 days ago) - New article: Supreme Court Finds For Monsanto In Seed Harvesting Case http://t.co/EAntMxrPzV ##patent
(about 5 days ago)